Clinical trials
Heart Diseases trials in the Netherlands with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 3 |
| 2023 | 2 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Unknown status | 6 |
| Active, not recruiting | 3 |
| Recruiting | 3 |
| Enrolling by invitation | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Maastricht University Medical Center | 3 |
| Abbott Medical Devices | 2 |
| Weill Medical College of Cornell University | 2 |
| Abiomed Inc. | 1 |
| Boston Scientific Corporation | 1 |
| Corcym S.r.l | 1 |
| Edwards Lifesciences | 1 |
| Elisabeth-TweeSteden Ziekenhuis | 1 |
| Erasmus Medical Center | 1 |
| J.J. Wykrzykowska | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Heart Diseases | 24 |
| Cardiovascular Diseases | 12 |
| Aortic Valve Stenosis | 5 |
| Coronary Artery Disease | 5 |
| Heart Valve Diseases | 5 |
| Myocardial Ischemia | 4 |
| Aortic Valve Disease | 2 |
| Arrhythmias, Cardiac | 2 |
| Arteriosclerosis | 2 |
| Coronary Disease | 2 |
Trials
Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.